NIH funds study to predict Parkinson’s risk with skin test
CND Life Sciences has been awarded a $3 million grant from the U.S. National Institutes of Health (NIH) to…
Articles by Andrea Lobo
Kneu Health gets $5.6M for Parkinson’s symptom-tracking app
Kneu Health said it has raised $5.6 million to expand its smartphone-based platform that helps doctors monitor symptoms of…
UK platform trial to test repurposed therapies for Parkinson’s
A new trial platform that will test multiple disease-modifying treatments for Parkinson’s disease is now recruiting participants in the…
Mission raises $13.3M for Parkinson’s treatment Phase 1b trial
Mission Therapeutics has raised $13.3 million to advance MTX325, its treatment candidate for Parkinson’s disease, into a Phase…
Parkinson’s gene therapy reduced alpha-synuclein in animal models
Shape Therapeutics’ SHP-201, an experimental gene therapy for Parkinson’s disease, significantly reduced the levels of alpha-synuclein — a…
Parkinson’s therapy is tolerated well, clearing path for Phase 2 trial
An experimental therapy being developed by Herantis Pharma for Parkinson’s disease was well tolerated and able to penetrate…
Trial of BIA 28-6156 for GBA1 Parkinson’s patients hits milestone
More than 80% of the people with Parkinson’s disease caused by GBA1 gene mutations who are enrolled in a…
Staying active in hospital speeds recovery, improves outcomes
People with Parkinson’s disease who stay active while in the hospital may recover faster and live longer, according to…
Advocates urge Congress to boost Parkinson’s research funding
More than 250 Parkinson’s patients, family members, scientists, and advocates gathered recently in Washington to urge Congress to expand federal…
Brain chemistry patterns differ in Parkinson’s, essential tremor
Parkinson’s disease and essential tremor are associated with distinct signaling patterns of two key brain neurotransmitters, dopamine and serotonin,…